Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Satralizumab in Generalized Myasthenia Gravis
jRCT2021210024Phase 3Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in myasthenia gravis (MG) comparing Satralizumab arm with Placebo arm (2 arms). Started Feb 2022; status: active, not recruiting.
02
Drugs
satralizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on jRCT2021210024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021210024.